Scorpius Sets New Standard With First cGMP Microbial Batches In San Antonio

Scorpius Holdings Inc., a comprehensive CDMO, has successfully completed its initial cGMP microbial batches at the San Antonio facility, marking a pivotal step towards supporting clinical manufacturing programs with an eye on future commercial ventures. The state-of-the-art facilities have garnered significant client interest, resulting in a backlog of bookings. This milestone showcases Scorpius' capability to adhere to stringent regulatory and client standards crucial for the contract manufacturing of microbial biologics. It also reflects the confidence clients have in their services. Scorpius is set to continue cGMP activities for the rest of the year.

Jeff Wolf, CEO of Scorpius Holdings, comment ed, "We are thrilled to have successfully completed our first cGMP microbial batches at the San Antonio facility. This milestone is a result of the dedication and collaboration among Scorpius’ manufacturing, process development, quality, and operations teams. The successful execution is a testament to the robust systems we have built and marks another step forward in our commitment to U.S. based cGMP activities for both current and future Scorpius clients."

He further added, "The Company remains dedicated to leveraging our advanced capabilities to support our clients' needs and contribute to the advancement of breakthrough therapies. With completion of this milestone, we believe that Scorpius is ready to further solidify its position as a leader in clinical scale microbial manufacturing, offering our clients unparalleled quality and service.”